Neoadjuvant Therapy in Differentiated Thyroid Cancer

Autor: Valerie H. Le, Rajan P. Dang, Marita S. Teng, Eric M. Genden, Brett A. Miles, Nadia Camille, Daniel C. McFarland, Krzysztof Misiukiewicz
Rok vydání: 2015
Předmět:
Oncology
Sorafenib
Niacinamide
medicine.medical_specialty
Indazoles
medicine.medical_treatment
Slovenia
030209 endocrinology & metabolism
Antineoplastic Agents
Review Article
Adenocarcinoma
lcsh:RC254-282
Targeted therapy
Pazopanib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Japan
Internal medicine
Medicine
Humans
Molecular Targeted Therapy
Thyroid Neoplasms
Thyroid cancer
Protein Kinase Inhibitors
Neoadjuvant therapy
Neoplasm Staging
Clinical Trials as Topic
Sulfonamides
Antibiotics
Antineoplastic
business.industry
Phenylurea Compounds
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Neoadjuvant Therapy
Laryngectomy
Pyrimidines
Treatment Outcome
chemistry
Doxorubicin
030220 oncology & carcinogenesis
Quinolines
Surgery
business
Lenvatinib
medicine.drug
Zdroj: International Journal of Surgical Oncology
International Journal of Surgical Oncology, Vol 2016 (2016)
ISSN: 2090-1410
Popis: Objectives. Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy.Methods. We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan.Results. These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data.Conclusions. Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.
Databáze: OpenAIRE
Externí odkaz: